Security key
87184Q107
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS)
CUSIP: 87184Q107
Q3 2016 13F Holders as of 30 Sep 2016
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 27,995,500
- Total 13F shares
- 12,757,094
- Share change
- +282,864
- Total reported value
- $176,293,302
- Price per share
- $13.87
- Number of holders
- 34
- Value change
- +$3,959,949
- Number of buys
- 26
- Number of sells
- 4
Report period
Q3 2016
Institutions
34
Top holders
10
SYRS full security history
Newer quarter: Q4 2016
Previous quarter: Q2 2016
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87184Q107
Recent filing periods:
Top shareholders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Flagship Ventures Fund IV General Partner LLC |
13F
|
Company |
17%
|
4,806,656
|
$87,241 | — | 30 Jun 2016 | |
| FMR LLC |
13F
|
Company |
11%
|
3,027,285
|
$37,841,000 | — | 30 Jun 2016 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
7.5%
|
2,095,220
|
$38,028,000 | — | 30 Jun 2016 | |
| Redmile Group, LLC |
13F
|
Company |
3.4%
|
946,182
|
$15,058,000 | — | 30 Jun 2016 | |
| Aisling Capital LLC |
13F
|
Company |
3.2%
|
908,565
|
$16,490,000 | — | 30 Jun 2016 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.73%
|
204,465
|
$3,711,000 | — | 30 Jun 2016 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.54%
|
150,000
|
$2,723,000 | — | 30 Jun 2016 | |
| Foresite Capital Management III, LLC |
13F
|
Company |
0.54%
|
150,000
|
$2,723,000 | — | 30 Jun 2016 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.25%
|
70,000
|
$1,271,000 | — | 30 Jun 2016 | |
| Casdin Capital, LLC |
13F
|
Company |
0.18%
|
50,000
|
$908,000 | — | 30 Jun 2016 | |
| Weiss Multi-Strategy Advisers LLC |
13F
|
Company |
0.16%
|
45,857
|
$832,000 | — | 30 Jun 2016 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.07%
|
20,000
|
$363,000 | — | 30 Jun 2016 |
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2016
As of 30 Sep 2016,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,757,094 shares.
The largest 10 holders included
Flagship Ventures Management, Inc., FMR LLC, DEERFIELD MANAGEMENT CO, Redmile Group, LLC, Aisling Capital LLC, BAKER BROS. ADVISORS LP, EVENTIDE ASSET MANAGEMENT, LLC, JPMORGAN CHASE & CO, BlackRock Fund Advisors, and Alyeska Investment Group, L.P..
This page lists
34
institutional shareholders reporting positions in this security
for the Q3 2016 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2016 vs Q2 2016 Across Filers
Q2 2016 holders
11
Q3 2016 holders
34
Holder diff
23
| Investor | Q2 2016 Shares | Q3 2016 Shares | Share Diff | Share Chg % | Q2 2016 Value $ | Q3 2016 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.